uniQure N.V. (0EE0.L)
USD 16.7
(1.06%)
USD 16.7
(1.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 624.01 Million USD | 172.55% |
| 2022 | 228.95 Million USD | 7.29% |
| 2021 | 213.4 Million USD | 121.17% |
| 2020 | 96.49 Million USD | -23.16% |
| 2019 | 125.57 Million USD | 33.16% |
| 2018 | 94.3 Million USD | -20.71% |
| 2017 | 118.93 Million USD | -6.08% |
| 2016 | 126.63 Million USD | -5.54% |
| 2015 | 134.05 Million USD | 109.18% |
| 2014 | 64.08 Million USD | 38.93% |
| 2013 | 46.12 Million USD | 479.87% |
| 2012 | 7.95 Million USD | -26.91% |
| 2011 | 10.88 Million USD | -9.52% |
| 2010 | 12.02 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 589.98 Million USD | -6.9% |
| 2024 Q2 | 633.73 Million USD | 1.68% |
| 2024 Q1 | 623.29 Million USD | -0.12% |
| 2023 Q2 | 589.44 Million USD | 170.1% |
| 2023 FY | 624.01 Million USD | 172.55% |
| 2023 Q1 | 218.23 Million USD | -4.68% |
| 2023 Q4 | 624.01 Million USD | 3.53% |
| 2023 Q3 | 602.76 Million USD | 2.26% |
| 2022 Q1 | 211.14 Million USD | -1.06% |
| 2022 FY | 228.95 Million USD | 7.29% |
| 2022 Q4 | 228.95 Million USD | 5.48% |
| 2022 Q3 | 217.06 Million USD | 1.09% |
| 2022 Q2 | 214.72 Million USD | 1.69% |
| 2021 Q1 | 135.16 Million USD | 40.08% |
| 2021 Q3 | 183.87 Million USD | 22.05% |
| 2021 Q4 | 213.4 Million USD | 16.06% |
| 2021 FY | 213.4 Million USD | 121.17% |
| 2021 Q2 | 150.65 Million USD | 11.46% |
| 2020 Q2 | 119.83 Million USD | 0.62% |
| 2020 FY | 96.49 Million USD | -23.16% |
| 2020 Q1 | 119.09 Million USD | -5.16% |
| 2020 Q4 | 96.49 Million USD | -21.31% |
| 2020 Q3 | 122.61 Million USD | 2.32% |
| 2019 Q4 | 125.57 Million USD | 3.47% |
| 2019 Q3 | 121.36 Million USD | 0.28% |
| 2019 FY | 125.57 Million USD | 33.16% |
| 2019 Q1 | 111.88 Million USD | 18.64% |
| 2019 Q2 | 121.02 Million USD | 8.17% |
| 2018 Q4 | 94.3 Million USD | 16.12% |
| 2018 Q3 | 81.2 Million USD | -9.89% |
| 2018 Q2 | 90.12 Million USD | -2.01% |
| 2018 Q1 | 91.97 Million USD | -23.54% |
| 2018 FY | 94.3 Million USD | -20.71% |
| 2017 FY | 118.93 Million USD | -6.08% |
| 2017 Q3 | 119.37 Million USD | -8.65% |
| 2017 Q1 | 123.9 Million USD | -2.15% |
| 2017 Q4 | 120.28 Million USD | 0.76% |
| 2017 Q2 | 130.67 Million USD | 5.46% |
| 2016 Q3 | 132.78 Million USD | -2.56% |
| 2016 FY | 126.63 Million USD | -5.54% |
| 2016 Q2 | 136.27 Million USD | -1.13% |
| 2016 Q1 | 137.83 Million USD | 2.81% |
| 2016 Q4 | 126.63 Million USD | -4.63% |
| 2015 Q2 | 126.75 Million USD | 107.69% |
| 2015 FY | 134.05 Million USD | 109.18% |
| 2015 Q4 | 134.05 Million USD | -4.07% |
| 2015 Q3 | 139.74 Million USD | 10.25% |
| 2015 Q1 | 61.03 Million USD | -4.77% |
| 2014 Q4 | 64.08 Million USD | 0.75% |
| 2014 Q2 | 63.31 Million USD | 18.17% |
| 2014 Q3 | 63.6 Million USD | 0.46% |
| 2014 Q1 | 53.58 Million USD | 16.16% |
| 2014 FY | 64.08 Million USD | 38.93% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q2 | 62.12 Million USD | 0.0% |
| 2013 Q4 | 46.12 Million USD | 5.67% |
| 2013 Q3 | 43.65 Million USD | -29.73% |
| 2013 FY | 46.12 Million USD | 479.87% |
| 2012 Q4 | 7.95 Million USD | 0.0% |
| 2012 FY | 7.95 Million USD | -26.91% |
| 2011 FY | 10.88 Million USD | -9.52% |
| 2010 FY | 12.02 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -315.857% |
| Dynavax Technologies Corporation | 375.02 Million USD | -66.394% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -28.014% |
| Perrigo Company plc | 6.04 Billion USD | 89.671% |
| Illumina, Inc. | 4.36 Billion USD | 85.707% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.797% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -218.803% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.094% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 96.966% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -143.302% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 91.22% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1573.332% |
| Waters Corporation | 3.47 Billion USD | 82.05% |
| Biogen Inc. | 12.04 Billion USD | 94.819% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -657.001% |
| Evolus, Inc. | 209.68 Million USD | -197.595% |
| Adicet Bio, Inc. | 37.12 Million USD | -1581.086% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -807.545% |
| bluebird bio, Inc. | 424.62 Million USD | -46.958% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 5.565% |
| FibroGen, Inc. | 585.72 Million USD | -6.537% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 87.312% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1673.935% |
| Homology Medicines, Inc. | 118.53 Million USD | -426.452% |
| Geron Corporation | 146.12 Million USD | -327.039% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 84.594% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -1.022% |
| Myriad Genetics, Inc. | 312.9 Million USD | -99.431% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -3009.058% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -148.803% |
| Zoetis Inc. | 9.29 Billion USD | 93.287% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1168.95% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 82.199% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 66.984% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 87.883% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1188.098% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 76.03% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -135.715% |
| Verastem, Inc. | 71.18 Million USD | -776.616% |
| Nektar Therapeutics | 267.04 Million USD | -133.675% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -57.081% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1451.283% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 74.056% |
| OPKO Health, Inc. | 622.47 Million USD | -0.247% |
| Exelixis, Inc. | 678.44 Million USD | 8.022% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 38.786% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -443.514% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -4878.61% |
| Imunon, Inc. | 8.53 Million USD | -7215.214% |
| Blueprint Medicines Corporation | 918.64 Million USD | 32.072% |
| Insmed Incorporated | 1.66 Billion USD | 62.448% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 62.168% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -394.864% |
| TG Therapeutics, Inc. | 169.08 Million USD | -269.056% |
| Incyte Corporation | 1.59 Billion USD | 60.809% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 47.367% |